trending Market Intelligence /marketintelligence/en/news-insights/trending/rg0fxBMOxmz_SApIjjWNJw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Japanese regulator approves Ironwood's irritable bowel syndrome drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Japanese regulator approves Ironwood's irritable bowel syndrome drug

Japan's Ministry of Health, Labor and Welfare approved Ironwood Pharmaceuticals Inc.'s LINZESS for the treatment of adults with irritable bowel syndrome with constipation.

The approval triggers a $15 million milestone payment from development and commercialization partner Astellas Pharma Inc., which secured the marketing approval.

Under the agreement, Astellas paid Ironwood a $30 million upfront licensing fee, a $15 million development milestone payment upon enrollment of the first patient in a phase 3 trial, and a $15 million milestone payment upon the new drug application submission. The agreement also provides for Ironwood to receive royalties, which escalate based on sales volume.

Data from a phase 3 trial in Japan indicate that patients treated with 500 mcg of linaclotide showed statistically significant improvement compared to placebo-treated patients.

Another phase 3 trial of the drug in patients with chronic constipation is ongoing in Japan, with top-line data expected in 2017.

Astellas is expected to launch LINZESS in the first half of 2017.